Kornimate/medical-research-clean huggingface dataset:
depression and anxiety reduction treatment for suicide

Conditions: Anxiety; Depression; Suicide

Summary: the purpose of this study is to test the effectiveness and usability of multiple computer-based treatments for mood and anxiety relevant risk factors. the target of the treatment is related to cognitive stress, which has been shown to be associated with a variety of negative mental health outcomes such as post-traumatic stress disorder, suicidal ideation, and substance use disorders.

darts is a newly developed computerized treatment targeting specific risk factors associated with suicide, mood, and anxiety symptoms. eligible individuals will be randomized to one of several conditions. in all conditions, participants will complete various self-report questionnaires and a neurophysiology assessment that involves an eeg. some participants will also be asked to complete four additional eeg assessments. in addition, all participants will be asked to complete a 1, 3, and 6-month follow-up appointment.

Eligibility criteria:
inclusion criteria: * at or above community sample mean on asi-3 * at or above community sample mean on inq-r * english speakers * 18 years of age or older exclusion criteria: * significant medical illness * current substance dependence * current or past psychotic-spectrum disorders * uncontrolled bipolar disorder * serious suicidal intent that warranted immediate treatment

Keywords: computerized intervention cognitive bias modification anxiety mood perceived burdensomeness thwarted belongingness suicide post-traumatic stress disorder
pathophysiologic mechanism for arrhythmias and impaired aerobic capacity in tetralogy of fallot and other congenital heart diseases

Conditions: Tetralogy of Fallot; Congenital Heart Disease

Summary: this study is being done to determine the mechanism(s) contributing to the onset of symptoms (i.e. shortness of breath and/or palpitations) as well as changes in heart structure in patients with congenital heart disease (chd)


Eligibility criteria:
inclusion criteria: * moderate (or greater) pr based on quantitative doppler echocardiography. * repaired tof * congenital heart disease diagnosis including but not limited to ebstein's anomaly, coarctation of the aorta (coa), fontan palliation, transposition of the great arteries, congenitally corrected transposition of the great arteries. exclusion criteria: * pregnant women * unable to undergo cmri
a randomized, parallel arm, comparative, open label, multicenter study of the activity and safety of two formulations of saquinavir in combination with other antiretroviral drugs

Conditions: HIV Infections

Summary: to evaluate the antiviral activity and safety of two formulations of saquinavir in combination with licensed nucleoside antiretroviral drugs.

patients are randomized to receive either hard gel or soft gel capsules of saquinavir in combination with at least one licensed nucleoside antiretroviral. treatment will continue for 48 weeks. after the first 16 weeks, patients will be given the opportunity to roll over to the saquinavir formulation of choice.

Eligibility criteria:
inclusion criteria patients must have: * hiv infection. * antiretroviral naiveness (i.e., less than 4 weeks of prior treatment) to at least one of the licensed nucleoside drugs. * no more than 2 weeks of prior treatment with a protease inhibitor. * no active opportunistic infection or other serious aids-defining condition. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * malabsorption or inadequate oral intake. * lab or clinical abnormality worse than grade 3 (other than exercise-induced cpk elevations). * unexplained, chronic diarrhea, defined as more than three loose stools per day persisting for 2 weeks or more within the month prior to study entry. * active malignancy or anticipated need for chemotherapy during the study. * anticipated need for disallowed medications during the study. concurrent medication: excluded: * other protease inhibitors. prior medication: excluded: * more than 4 weeks of the prior nucleoside antiretroviral selected for the patient's regimen. * more than 2 weeks of any protease inhibitor.

Keywords: drug therapy, combination acquired immunodeficiency syndrome aids-related complex antiviral agents saquinavir
the efficacy and safety study of high dose donepezil in parkinson's disease with dementia

Conditions: Parkinson's Disease

Summary: the purpose of this study to evaluate the safety and efficacy of high-dose donepezil (23mg) in parkinson's disease with dementia compared to standard dose donepezil.

this study is open-label, prospective, randomized paralleled study. the investigators evaluate the efficacy of high-dose donepezil in patients with parkinson's disease with dementia (pdd) who have taken standard donepezil (10mg) for 12 weeks. the participants, who sign the informed consent, are assigned into two groups randomly (high-dose donepezil group and standard donepezil group). all participants will be maintained the medication for 24 weeks and assessed cognitive function at 24 weeks. they will visit to clinic for 3 times (4, 12, 24 weeks) to assess cognitive function and adverse event. after the end of study, all participants were administrated by standard dose donepezil again.

Eligibility criteria:
inclusion criteria : * patients diagnosed as parkinson's disease according to queen brain bank criteria * patients who have been diagnosed as dementia after diagnosing parkinson's disease at least 1 year. * patients with hoehn and yahr staging from 2 to 4 * patients with mmse score from 10 to 24 * patients who have taken donepezil for at least 12 weeks before screening period * patients whose medications for parkinson's disease have not change for 1 month * patients who give informed consent exclusion criteria : * patients who cannot be performed neuropsychiatric test because of hearing and visual difficulty * patients who have taken medicine affecting cognitive function such as anticholinergic drug and memantine -patients diagnosed as dementia with lewy body and vascular dementia- * patients who have history of neurosyphilis, head trauma, encephalitis or other movement disorders * patients who have psychiatric disease * except patients who are stable state under antidepressant or atypical neuroleptics * patients with child-bearing periods * patients who have severe liver or kidney disease necessary for aggressive treatment * patients who have gastrointestinal disease needed for treatment * patients who cannot taken tablet per oral * patients who are participated in other clinical trial except observational study

Keywords: parkinson's disease dementia
electrochemotherapy with carboplatinum plus bleomycin versus bleomycin alone in vulvar cancer

Conditions: Vulvar Cancer

Summary: patients with vulvar cancer who underwent multiple treatments (surgery and radiation therapy or chemoradiation, radiation therapy or chemoradiation and chemotherapy), or patients not eligible for standard therapies. the study aims to: * evaluate the oncology response to electroporation after administration of bleomycin (blm) + carboplatinum (cbp )to blm alone in terms of local progression-free survival (lpfs) in women with relapsed vulvar cancer after multimodal treatments. * compare quality of life (hr-qol) in the two groups of patients with questionnaires (fact-v, fact-pal, e5-5l-d5). * to compare overall survival in the two study arms. * to compare local and systemic toxicity, morbidity and mortality, intraoperative and post-operative complications among the two study arms. * to compare costs and cost-effectiveness between the two study arms.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * recurrent vc confirmed by histological examination * patient who underwent multiple treatments (surgery and radiation therapy or chemoradiation, radiation therapy or chemoradiation and chemotherapy). * patient not eligible for standard therapies (surgery, radiation therapy and systemic chemotherapy in case of metastatic disease) due to the performance status (ecog performance status ≥ 3 ) * life expectancy more than three months * measurable disease according to recist 1.1 * adequate bone marrow, liver, and kidney function (creatinine \<1.5 mg/dl), and coagulation parameters as follows: * bone marrow (hemoglobin ≥ 8.0 g/dl with or without transfusion support, platelet count ≥ 75 × 109/l?) o inr \>1.5; * aspartate aminotransferase (ast)/serum glutamic-oxaloacetic transaminase (sgot), alanine aminotransferase (alt)/serum glutamic-pyruvate transaminase (sgpt) ≤3.0 × upper limit of normal (uln) * total bilirubin ≤2.0 × uln or ≤3 × uln except for subjects with gilbert's syndrome * serum creatinine \ 30 ml/min all blood assessments must be performed within 15 days from ect treatment. * for females of childbearing potential, a negative serum pregnancy human chorionic gonadotropin (hcg) pregnancy test within 72 hours of study day 1. * signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply the study requirements. exclusion criteria: * history of other malignancies in the previous five years, except basal cell carcinoma of the skin. * history of psychological, familial, sociological, or geographical condition potentially preventing compliance with the study protocol and follow-up schedule. * allergic reactions to the two chemotherapy drugs (blm and auc2-carboplatin) and/or their excipients. * evidence of pulmonary fibrosis.
scleral response to intraocular pressure (iop)

Conditions: Glaucoma, Open-Angle

Summary: the study evaluated changes in the depth of the lamina cribrosa at different eye pressures.

participants were glaucoma patients who during routine care were observed at different eye pressures. images taken with an optical device that is routinely used in such patients were analysed.

Eligibility criteria:
inclusion criteria: * glaucoma patients exclusion criteria: * non-glaucoma patients

Keywords: biomarker
impact of viagra on sexual satisfaction of men with mild erectile dysfunction who are sexually dissatisfied

Conditions: Impotence

Summary: men's quality of life (qol) is potentially affected by mild erectile dysfunction (ed) to the same extent as it is by moderate and severe ed. this study will provide controlled clinical data measuring efficacy, qol parameters and satisfaction changes in men with mild ed treated with viagra versus those treated with a placebo. with an open-label extension, this study will also provide all study subjects the opportunity to receive the active drug treatment for 6 weeks.


Eligibility criteria:
inclusion criteria: * men above age of majority * mild erectile dysfunction (iief-ef 22-25) and sexual dissatisfaction (iief-os 7 or less) exclusion criteria: * use of more than 4 doses of any pde5 inhibitor in the past 12 weeks and use of any pde5 inhibitor in the past 4 weeks * subjects currently taking any other commercially available drug or non-drug treatment for ed
effects of quinapril 40 mg with alpha lipoic acid or placebo on diabetes and hypertension

Conditions: Diabetes; Hypertension

Summary: we will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes mellitus and hypertension. we will determine whether the combination of quinapril and lipoic acid as compared to quinapril and placebo provides benefit on systemic blood pressure and proteinuria.

the participant will be randomized to either quinapril 40 mg and alpha lipoic acid versus quinapril 40 mg and placebo for 8 weeks. there will be a wash out period of 4 weeks between the cross over. the participant will be assigned the cross over for 8 weeks on the opposite therapy.

Eligibility criteria:
inclusion criteria: patients who have a diagnosis of diabetes mellitus as defined by fasting blood glucose levels greater than ot equal to 126mg/dl and a systolic bp greater than 125 mm hg at the time of screening will be included in the study. patients may be on antihypertensive medication but not on ace inhibitor or arb therapy at the time of enrollment. exclusion criteria: systolic blood pressure \> 180 mmhg creatinine \> 2.5 mg/dl glycosylated hemoglobin \> 7.5% congestive heart failure (nyha class ii, iii or iv) coronary angiography planned prior to baseline sampling chronic autoimmune disease chronic inflammatory disease or known cancer in evolution life expectancy \< 1 year immunosuppressives or treatment with any other investigational drug within the last 30 days pregnant or nursing women participants who experience any side effects to quinapril and/or alpha lipoic acid women of childbearing potential women of childbearing potential enrolled in the study should use one of the acceptable methods of birth control as listed below 1. abstinence, meaning a total lack of any sexual activity. 2. oral contraceptives (the "pill"), 3. contraceptive injections, 4. intrauterine device, 5. double-barrier method (diaphragm or condom + spermicidal cream), 6. contraceptive patch, or 7. male partner sterilization. pregnancy any pregnancy that occurs during study participation must be reported to the principal investigator and the study coordinator at the earliest. the pregnancy must be followed up to determine outcome and status of the mother and child. to ensure subject safety, any subject that becomes pregnant during the study will be discontinued from the trial.

Keywords: brachial artery reactivity
effects of aerobic exercise, cognitive remediation and combined intervention in schizophrenia

Conditions: Schizophrenia; Psychosis

Summary: tracking down the efficacy of a combined intervention of cognitive remediation (cr) and phisycal activity (aerobic exercise, ae) in patients diagnosed with schizophrenia

the investigators will address the following objectives: * primary objective: o assess, through a randomized controlled trial (rct), the efficacy and feasibility of a combined intervention (cr + ae) in patients with schizophrenia. the primary outcome measure will be cognitive performance, while secondary outcomes will include scales for the assessment of psychopathology, daily functioning, and quality of life. * secondary objectives: to evaluate changes in bio-physical and laboratory metabolic parameters, as well as in neurotrophic and neuroinflammatory factors. furthermore, multimodal magnetic resonance imaging (mri) parameters will be evaluated after the interventions, and their relationship with observed cognitive improvements will be explored.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with schizophrenia 2. age 18-65 years 3. psychopathological stability 4. ability to provide informed consent exclusion criteria: 1. comorbidity with intellectual disability and neurological disorders. 2. ongoing treatment with cr or ae. 3. specific contraindications for ae.

Keywords: cognition pshysical activity metabolic syndrome
a study of obinutuzumab in chinese participants with cd20+ malignant disease

Conditions: Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

Summary: this multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (cd) 20 positive (+) malignant disease. participants will receive multiple doses of obinutuzumab. the anticipated time on study treatment is 24 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of cd20+ b-cell lymphoma or b-cll * refractory/relapsed cll, fl, and dlbcl * at least 1 measurable lesion (greater than \[\>\] 1.5 centimeters \[cm\] in its largest dimension) with the exception of cll * eastern cooperative oncology group (ecog) performance status of 0 or 1 * life expectancy \>6 months exclusion criteria: * prior use of any investigational antibody therapy within 6 months of study start * prior use of any anti-cancer vaccine * prior administration of rituximab within 3 months of study start * prior administration of radioimmunotherapy 3 months prior to study entry * central nervous system lymphoma * history of other malignancy * evidence of significant, uncontrolled concomitant disease * abnormal laboratory values * patients with progressive multifocalleukoencephalopathy (pml) * infection with human immunodeficiency virus (hiv), hepatitis b or hepatitis c
differences in ecg- vs. prolonged cardiac monitor-detected atrial fibrillation in stroke patients (delimit af-stroke)

Conditions: Stroke; Atrial Fibrillation; TIA

Summary: the present study is an investigator-initiated, single-center, retrospective study based on data from the london ontario stroke registry (losr), aiming to compare the characteristics and outcomes of ecg-detected and device-detected atrial fibrillation in patients with ischemic stroke and transient ischemic attack.

patients with ischemic stroke and transient ischemic attack (tia) without known atrial fibrillation (af) are investigated with prolonged cardiac monitoring (pcm) to detect af. it is unclear if af detected on 12-lead ecg after stroke occurrence bears the same risk of stroke as device-detected af. the investigators hypothesize, that device-detected af has a lower risk of ischemic stroke recurrence. the investigators will conduct a retrospective analysis of prospectively collected data from consecutive patients enrolled in the london ontario stroke registry, (ontario, canada). the primary outcome will be a recurrent ischemic stroke at the end of the available follow-up window. the investigators will include ischemic stroke and tia patients with ecg-detected af and those with device-detected af on at least 7 days of holter monitoring.

Eligibility criteria:
inclusion criteria: * age ≥18 years * patient with a diagnosis of ischemic stroke or tia. * ecg-diagnosed af or pcm-detected af post ischemic stroke or tia exclusion criteria: * individuals younger than18 years-old * patients without is or tia diagnosis
efficacy of lactobacillus rhamnosus lra05 in gestational diabetes

Conditions: GDM

Summary: this study aims to comprehensively evaluate the multifaceted impacts of lactobacillus rhamnosus lra05 on patients with gestational diabetes. initially, the study will investigate the effects of lra05 on improving patients' blood glucose levels and gut microbiota. additionally, the study will assess the impact of this strain on patients' blood lipid levels, inflammatory markers, and body mass index (bmi). furthermore, the study will also focus on its effects on thyroid function, vaginal microbiota, and bile acid metabolism in patients with gestational diabetes.


Eligibility criteria:
inclusion criteria: 1. women diagnosed with gestational diabetes mellitus (gdm) at 24 weeks of gestation. diagnostic criteria for gdm: abnormal oral glucose tolerance test (ogtt) with an 82.5g glucose load during the 24th week of pregnancy (defined as meeting one or more of the following plasma glucose thresholds: fasting ≥ 5.1 mmol/l, 1-hour ≥ 10 mmol/l, or 2-hour ≥ 8.5 mmol/l). 2. pregnant women aged 18 to 50 years. 3. singleton pregnancy with a fetus confirmed to be structurally and chromosomally normal via ultrasound or other prenatal diagnostic methods. 4. no history of chronic diseases, including immune deficiency, hypertension, diabetes, kidney disease, or liver disease. 5. no consumption of probiotic-containing foods (e.g., yogurt, fermented foods, soybean paste) within the two weeks prior to the study. 6. willing and able to provide written informed consent. 7. capable of complying with the study protocol and follow-up requirements. exclusion criteria: 1. those who have taken items with similar functions to the test product in the short term, which may affect the judgment of the results. 2. those with other endocrine diseases or currently using medications that affect blood glucose control. 3. those with severe cardiovascular, kidney, or liver diseases. 4. those with immunodeficiency diseases or currently using immunosuppressive agents. 5. those with severe gastrointestinal diseases that may affect the absorption or metabolism of probiotics. 6. those currently using other medications that may affect blood glucose control or lipid levels. 7. those with a history of allergy to probiotics or any components of the study products. 8. those with unhealthy lifestyle habits, such as smoking, alcohol consumption, or drug abuse. 9. those who do not consume the test samples as required or do not follow up on time, resulting in uncertain efficacy. 10. study participants deemed unsuitable by other researchers.
study of cabozantinib in combination with atezolizumab versus sorafenib in subjects with advanced hcc who have not received previous systemic anticancer therapy

Conditions: Hepatocellular Carcinoma

Summary: this phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (hcc) who have not received previous systemic anticancer therapy. a single-agent cabozantinib arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.

this is a multicenter, randomized, open-label, controlled phase 3 trial of cabozantinib in combination with atezolizumab versus sorafenib in adults with advanced hcc who have not received previous systemic anticancer therapy in the advanced hcc setting. the primary objective of this study is to evaluate the effect of cabozantinib in combination with atezolizumab on the duration of progression-free survival (pfs) and duration of overall survival (os) versus sorafenib. the secondary objective is to evaluate the activity of single-agent cabozantinib compared with sorafenib in this patient population.

Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of hcc or clinical diagnosis of hcc in cirrhotic patients by ct or mri per the aasld 2018 or easl 2018 guidelines. * the subject has disease that is not amenable to a curative treatment approach (eg, transplant, surgery, ablation therapy) or locoregional therapy (eg, tace). * measurable disease per recist 1.1 as determined by the investigator. * barcelona clinic liver cancer (bclc) stage category b or c. * child-pugh score of a. * eastern cooperative oncology group (ecog) performance status of 0 or 1. exclusion criteria: * known fibrolamellar carcinoma, sarcomatoid hcc or mixed hepatocellular cholangiocarcinoma. * prior systemic anticancer therapy for advanced hcc including but not limited to chemotherapy, small molecule kinase inhibitors, and immune checkpoint inhibitors (icis). subjects who have received local intratumoral or arterial chemotherapy are eligible; local anticancer therapy within ≥ 28 days before randomization * radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 8 weeks prior to randomization. * known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 8 weeks prior to randomization. * concomitant anticoagulation with oral anticoagulants

Keywords: liver cancer hepatocellular carcinoma
prosthesis infection and one-step exchange: pretreatment by targeted antibiotic therapy in at-risk patients

Conditions: Prosthetic Joint Infection; Antibiotic Resistant Infection

Summary: one-step exchange arthroplasty is more and more used in the treatment of chronic infections, especially in patients at risk anesthetic. this strategy is not recommended in patients infected with multidrug-resistant organisms or difficult to treat because of a risk of bacterial persistence on the new implant. antibiotic pretreatment by a narrow-spectrum molecule and for which resistance acquisition is difficult might be of interest to try to reduce the inoculum and avoid contamination of the new implant.


Eligibility criteria:
inclusion criteria: * patients having had a antibiotic pretreatment targeted before a one step exchange arthroplasty exclusion criteria: * none

Keywords: bone and joint infection antibiotic pretreatment